Transdermal nicotine during cue reactivity in adult smokers with and without anxiety disorders

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

Transdermal nicotine almost doubles tobacco cessation rates; however, little is known about what happens to smokers during the quit process when they are wearing the nicotine patch and are confronted with high-risk smoking triggers.

This is particularly important for smokers with psychological disorders who disproportionately represent today's smokers and have more trouble quitting.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.

Urge to smoke was evaluated during a 5-hr patch absorption period (reflecting general smoking deprivation) and during imaginal exposure to theoretically high-risk triggers containing smoking cues, anxiety cues, both, or neutral cues.

What Was Measured

The subject headings attached to it are Affect, Anxiety Disorders, Cues, Imagination, Motivation, Risk Factors and Smoking.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

The publication is from 2012 (Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.